



# How GTSN Saved an Employer Over \$800K on a Single Member's Tepezza Infusions

## The Problem

Tepezza, a specialty medication used to treat Thyroid Eye Disease (TED), is administered once every three weeks for a total of eight doses, and when delivered through outpatient hospital facilities often incurs significant buy-and-bill markups.

When one patient covered under a GTRx managed plan began receiving Tepezza infusions in an outpatient setting, the high treatment costs threatened the plan's financial sustainability.

## The Solution

GTRx quickly identified the case for intervention and conducted a rapid assessment. GTRx confirmed the patient met the criteria required for home infusion therapy, a safe and effective alternative to hospital-based administration.

Working collaboratively with the provider, care team, and member, GTRx coordinated a seamless transition to the home infusion setting, and ensuring uninterrupted treatment.



## The Result

This site-of-care optimization led to net savings of over \$800,000 for the plan over duration of the patient's treatments without compromising patient safety or outcomes.

Beyond immediate financial savings, this intervention underscores the importance of effective J-code cost management proactive case identification, rapid implementation, and a commitment to smarter specialty drug management.

**MEASURABLE SAVINGS.  
IMPROVED OUTCOMES.  
RELIABLE PARTNERSHIPS.**

See how GTRx can help your clients unlock savings and improve patient care. Contact GTSN today to learn more.

**Hy Byrd**  
Chief Operating Officer

